Table 3.

Molecular predictors of OS

Genotype	No. of patients	Median OS, mo	Univariable analysis		Multivariable analysis
			HR	P	HR	95% CI	P
Total cohort	247	15
NGS result			0.46	.02*	1.34	0.54-3.33	.52
No mutation	28	24
≥1 mutation	213	14.1
No. of mutations				.005*	1.22	1.03-1.44	.02*
TET2			0.89	.67
Mut	41	16.1
WT	188	14.4
ASXL1			0.84	.49
Mut	47	18.6
WT	200	14.4
TET2-mut/ASXL1-wt and TP53-wt			0.51	.13
Present	21	16.1
Other	218	14.4
DNMT3A			1.37	.24
Mut	35	11.4
WT	193	15.5
EZH2			2.83	<.001*	2.41	1.03-5.64	.04*
Mut	15	9.9
WT	232	16.1
DNA methylation mutation			0.96	.83
Mut	79	14.2
WT	148	14.4
Epigenetic regulation mutation			1.04	.82
Mut	120	14.2
WT	115	15.5
SF3B1			0.77	.57
Mut	13	18.5
WT	217	14.4
Any spliceosome			0.68	.07	1.06	0.58-1.95	.84
Mut	77	19.1
WT	152	13.1
RUNX1			1.09	.78†
Mut	24	12.4
WT	223	15.5
Signaling pathway			1.15	.61
Mut	32	14.4
WT	196	14.5
TP53			2.82	<.001*	2.33	1.41-3.85	.001*
Mut	82	9.7
WT	165	21.7

HR, hazard ratio.

^*Denotes statistical significance (P < .05).

^†Associated with a statistically significant (P < .001) impact on OS when stratifying by both RUNX1 and TP53 genotype (see supplemental Figure 2).